Objective: To explore the clinical application of recombinant human endostatin (Endostar) in the treatmentof patients with non-small cell lung cancer (NSCLC) in Chinese mainland. Materials and
Methods: A total of75 patients diagnosed as NSCLC were randomly divided into control group (37 cases) and treatment group(38 cases). Control group was treated with postoperative complementary chemotherapy containing two-agentplatinum protocol on postoperative d21, 3 weeks as a cycle, for totally 4~6 cycles. On this basis, treatment groupwas added with Endostar 7.5 mg/m2 on postoperative d8~9, 3~4 h/time, qd, 14 weeks as a cycle, for totally 4cycles. The interval between every two cycles was 7 d. The 5-year progression-free survival (PFS), 5-year survivaltime and complications in both groups were observed.
Results: Compared with control group, the average PFSincreased evidently in treatment group by 9.8 months (41.6 months vs. 31.8 months), and there was significantdifference (P<0.05). And the median PFS was 42.5 months in treatment group, obviously longer than that incontrol group (33.7 months) by 8.8 months (P<0.05). Additionally, the 5-year overall survival rate (OS), averagesurvival time and median survival time (MST) were 47.4%, 50.1 months and 59.3 months in treatment group,significantly higher than the 29.7%, 42.1 months and 43.5 months in control group (P<0.05). Only 1 patientshowed poor healing of surgical wound in treatment group, but no surgery-associated complication was foundin control group. Moreover, the postoperative complementary therapy-connected complication rates were63.2% (24/38) and 59.5% (22/37) in treatment group and control group respectively, but there was no significantdifference (P>0.05).
Conclusions: The application of Endostar combined with sensitive platinum-containedchemotherapeutic agents in the postoperative complementary chemotherapy can be widely used in clinic becauseit can significantly prolong the long-term survival time of patients with NSCLC.